Does Medicare Cover Retatrutide? Your Options Now and What Could Change

By The RX Index Editorial Team · Last verified October 2026

No. Medicare doesn't cover retatrutide as a routine prescription today—not through Part D, Medicare Advantage, or the $50 GLP-1 Bridge. It isn't FDA-approved. Lilly plans to apply in early 2027. Medicare can cover routine care in qualifying trials; future approval for sleep apnea or knee osteoarthritis pain could open a Part D path. (FDA; Lilly; Medicare trial rules)

Below: every Medicare door we checked on October 16, 2026, the $50 drugs you may qualify for instead, and the six gates that shape future coverage.

One honest limit first. No web page, including this one, can tell you whether you'll qualify for anything. Your prescriber and the Medicare plan or program involved make that call. What we can do is show you exactly which question to ask, and who to ask it.

RX Index Decision Verdict: For a Medicare-covered GLP-1 now, check the $50 Bridge or your Part D plan for an approved medicine. Treat retatrutide as a later decision.

• Best for: People on Medicare who want covered treatment this year.
• Not ideal for: Anyone hoping Medicare will pay for retatrutide soon, or anyone looking for a retatrutide seller.
• The factor that matters most: Why the drug is prescribed. Medicare treats a weight-loss prescription very differently from one for diabetes or sleep apnea.

Retatrutide and Medicare: every door, checked October 16, 2026

None of the paths below covers retatrutide as a routine prescription today. That includes Part D, Medicare Advantage, Medigap, the $50 Medicare GLP-1 Bridge, and the BALANCE Model. Medicare can cover some related care in a qualifying clinical trial; that is different from paying for retatrutide.

Here's the whole map in one place.

The $50 headline you may have seen is real. It just isn't a retatrutide price.

If you're wondering whether one of the $50 drugs could work for you, Medicare's own page lists the rules and has a short eligibility check.

Why doesn't Medicare cover retatrutide?

Two locks stand in the way. First, retatrutide lacks the FDA approval needed for routine prescription coverage. Second, even after approval, federal rules bar Part D from covering drugs when they're used for weight loss. (FDA; Part D rules)

Investigational means a drug is still being tested and isn't approved for regular prescriptions. The FDA says retatrutide hasn't been found safe and effective for any condition yet (FDA, October 2026).

Think of your Part D plan as a restaurant menu. Retatrutide isn't on the menu at all yet. And the "weight loss" section of the menu has been closed by law since Part D began. Right now there's one temporary side door—the Bridge—and retatrutide isn't on its list.

Changing plans doesn't fix this. Neither does an appeal. Neither one makes retatrutide an approved, covered prescription today.

The right GLP-1 path for someone on Medicare isn't the same for everyone. It depends on whether you have Part D, whether you have diabetes or sleep apnea, your BMI, your budget, and whether you want a shot or a pill. The RX Index's Find My GLP-1 Path tool asks a few quick questions and shows the GLP-1 paths and providers that fit your goals, budget, insurance, and situation—free, about 2 minutes, no signup. It doesn't confirm your Medicare coverage. The rules below show what to ask your prescriber and plan.

Is retatrutide covered by the $50 Medicare GLP-1 Bridge?

No. The Medicare GLP-1 Bridge covers three approved drugs—Foundayo, Wegovy, and the Zepbound KwikPen—from July 1, 2026 through December 31, 2027. Eligible people pay $50 for a one-month supply.

The Bridge is a short-term program from CMS, the agency that runs Medicare. It runs outside your regular Part D plan. Your plan doesn't have to sign up for you to use it (CMS).

None of these drugs is retatrutide, and none is "the same" as retatrutide. They're different approved medicines.

Source: CMS Information for Providers, modified August 6, 2026. CMS says this list "may be updated," but it hasn't named retatrutide. For exact product codes, see our Medicare GLP-1 Bridge tracker.

What the $50 does and doesn't cover

The $50 is a medicine copay. It isn't your whole bill.

• It covers a one-month supply—28 or 30 days, depending on the drug (Medicare.gov).
• Your Part D deductible does not apply, and the $50 does not count toward your Part D yearly out-of-pocket limit (CMS).
• Extra Help can't lower it, and you can't spread it out with the Medicare Prescription Payment Plan. (CMS; Medicare.gov)
• Doctor visits, lab tests, and pen needles are separate. We couldn't verify a standard price for those, so don't assume they're free.

Who qualifies for the Bridge

You must be 18 or older, have an eligible Medicare drug plan, and be prescribed the drug to lose weight and keep it off, with ongoing structured nutrition and physical activity. Your prescriber must confirm the rules through prior authorization. Then you need one of these, measured when you started a GLP-1:

BMI is a number based on your height and weight. If you don't know yours, the NHLBI BMI calculator works, but your records from when you started matter most.

"Uncontrolled high blood pressure" has a strict meaning here: the top number is above 140 or the bottom number is above 90, despite taking two blood-pressure medicines at the same time (CMS). Your prescriber must confirm the diagnosis and treatment.

Eligible drug plans: a standalone Part D plan, a Medicare Advantage HMO, HMO-POS or PPO with drug coverage, a Special Needs Plan with Part D, an employer or union retiree plan with Part D, or the LI NET temporary drug-coverage program. Some other plan types, including private fee-for-service plans, cost plans, and PACE, do not qualify on their own. A separate eligible Part D plan can qualify where that combination is allowed. Ask your plan or 1-800-MEDICARE before changing coverage. (CMS plan-type rules)

When your Part D plan is the right door instead

The Bridge is only for weight management. If you have one of these, CMS directs you to your regular Part D plan instead—even if your BMI fits. That is a different coverage path, not a guarantee your plan will approve the medicine:

• Type 2 diabetes
• Moderate-to-severe obstructive sleep apnea
• Noncirrhotic MASH (a type of fatty liver disease) with moderate-to-advanced scarring, stages F2–F3

You're also not eligible if you already get a GLP-1 through your Part D plan (Medicare.gov).

Heart history works a little differently. A past heart attack or stroke doesn't shut you out. But if the drug is prescribed to lower your risk of heart attack and stroke, CMS says that prescription goes to your Part D plan (CMS).

Medicare.gov's consumer page just says "fatty liver disease." The CMS rule for doctors is narrower. If a liver diagnosis is in your records, let your prescriber sort out which door applies. (Medicare.gov; CMS clinical guidance)

How the Bridge actually works

1. Your prescriber sends a prescription for a Bridge drug to your pharmacy.
2. The pharmacy sends the claim to the Bridge. You don't need a Part D denial first.
3. The pharmacy asks your prescriber for a prior authorization. That's a permission slip—your doctor confirms you meet the rules.
4. The Bridge sends its decision within 72 hours of the submission. You get a mailed notice; your prescriber gets the decision electronically or by fax.
5. Approval lasts through December 31, 2027, including refills and dose changes for that drug, while you remain eligible. Switching to another covered GLP-1 needs a new prior authorization. Retatrutide is not a covered choice. (CMS process; CMS refill and switching rules)

There's no formal appeal. If the answer is no, your prescriber can resubmit with corrected or new information (CMS).

An existing approval does not override a later eligibility change. For example, getting a GLP-1 paid by Part D or moving to an ineligible plan type can end Bridge eligibility. And don't pay cash expecting the Bridge to pay you back later—it does not accept patient reimbursement claims. (CMS pharmacy rules)

Here's a hypothetical. Say you started a GLP-1 with a BMI of 37, and today you're at 32. That lower BMI alone doesn't rule you out. CMS looks at your BMI when you started; the other rules still apply. Ask your original prescriber for that record. (CMS initiation-BMI rule)

For every step in more detail, see our Medicare GLP-1 Bridge guide.

Find your situation: the right Medicare next step

Waiting for retatrutide is a choice, not a coverage plan. Whether to start something now is a decision for you and your clinician. This table shows the next step that fits each common Medicare situation.

Not sure if you have drug coverage? Ask your pharmacist to check your plan card, or call 1-800-MEDICARE (1-800-633-4227). An "Rx" symbol alone does not confirm that your plan type qualifies.

Need help comparing treatment and care options after checking the Medicare rules? The tool can suggest options to review; your prescriber and plan confirm coverage.

What to ask your doctor or pharmacist

The fastest way forward is one clear conversation. Confirm the medicine, then confirm the payment door: regular Part D or the Bridge. Here's a message you can bring, copy, or paste into your patient portal.

I have Medicare and was hoping retatrutide might be covered. I understand it isn't FDA-approved yet, so it isn't a regular prescription option. Can you help me check which approved medicine and which Medicare payment path fit my needs? My drug plan is: ____________ (or "not sure"). If I've taken a GLP-1 before, can you check my BMI and diagnoses from when I first started? Should my prescription go through my regular Part D plan or the Medicare GLP-1 Bridge? Does any past Medicare-paid GLP-1 affect that? If the Bridge fits, can you send the prescription for an eligible drug and complete the prior authorization when the pharmacy asks? What might I owe for the medicine, visits, lab tests, and supplies? If a clinical trial or Lilly's expanded access makes more sense, who supplies the drug, and what other costs might Medicare, the study, or I pay?

This is a set of questions, not an application, an appeal, or a request for retatrutide.

When could Medicare cover retatrutide? The six gates

Not as a routine prescription before FDA approval. Lilly's published plan is to submit in the first quarter of 2027. The FDA's usual review goals do not set an earliest approval date. Even after approval, Medicare coverage depends on the approved use, the coverage rules, and the drug plan. (Lilly, September 29, 2026; FDA review goals)

No approval date is confirmed. The timing below is an example based on published goals, not a forecast. The last two gates describe different payment paths—not two steps everyone must clear.

For example, a January–March 2027 submission would put the usual priority-review goal around September–November 2027, or the standard-review goal around January–March 2028. That assumes the original-BLA framework, an accepted application, and no review extension. These are action goals, not minimum waits or promised approvals. (FDA goals, pages 4 and 6)

Our read: Don't plan your care or budget around retatrutide coverage in 2027 or 2028. Neither is confirmed. If the FDA approves it for sleep apnea or knee osteoarthritis pain, that could create a Part D path for that use without waiting for a weight-loss program. Approval still would not guarantee your plan pays.

Why the label matters more than the drug

Medicare's weight-loss ban applies to the use, not the drug. That's why Part D can already cover Zepbound for sleep apnea, and why Medicare.gov sends people with sleep apnea to their Part D plan (Medicare.gov).

So the words on retatrutide's future label matter a lot. A weight-loss-only label runs into the ban. A sleep apnea or knee osteoarthritis pain label could be a use Part D plans are allowed to cover. Each plan would still decide.

Don't assume retatrutide will be covered "for diabetes." Lilly's July 2026 statement named obesity, knee osteoarthritis pain, and sleep apnea as uses supported for submissions. It did not confirm a diabetes filing or an approved diabetes use. (Lilly, July 23, 2026)

What could move the date

• Faster FDA review. The review track is not confirmed in the sources checked. A goal is not a minimum wait. See priority vs. standard review.
• The approval pathway. Lilly and the FDA have disputed whether retatrutide qualifies as a biologic. A September 30, 2025 court order required FDA to reconsider part of its classification decision. It did not approve retatrutide or set a review date. Lilly's later published plan is a biologics application.
• CMS adding new drugs. BALANCE's first round required drugs to be approved, or expected to be approved, for weight management by January 1, 2027. Lilly's Q1 2027 submission plan does not fit that approval cutoff. CMS expects to renew negotiations as new products arrive; that does not promise a deal for retatrutide. The separate Bridge list can also be updated. (CMS BALANCE rules; Bridge product-list rules)
• Congress. A change in the law could reopen weight-loss coverage. The current Part D rules still exclude drugs used for weight loss. (Current Part D definition)

For what happens after December 2027, see what happens after the Bridge ends.

Trials and early access: who pays for what?

Medicare won't pay for retatrutide itself, but it can pay for routine care if you join a qualifying clinical trial. Lilly's expanded access program is a narrow, doctor-requested exception, and Lilly says it supplies the drug at no cost. Neither one is a Medicare benefit for retatrutide.

Clinical trials

Medicare's national trial rule separates covered routine care from costs it does not pay (NCD 310.1):

Trials under an FDA Investigational New Drug application (IND) can automatically meet CMS's scientific qualifying rules. They must still test care within a Medicare benefit that is not excluded by law, and have a treatment purpose. Treatment trials must enroll people with a diagnosed disease, not healthy volunteers. An IND is not a promise that Medicare pays every bill. (NCD 310.1)

With Original Medicare, your usual share still applies—often 20% of the Medicare-approved amount after the Part B deductible. (Medicare.gov)

Medicare Advantage is different. For trials covered by this national rule, Original Medicare generally pays the trial services. Your plan pays the extra amount needed to keep your share at its in-network rate. You do not owe Original Medicare Part A or B deductibles for those trial services. A plan cannot require prior authorization just to join a Medicare-qualified trial it does not sponsor. Tell your plan and study team before bills are sent so they use the right process. (42 CFR 422.109(e); NCD 310.1)

Say you're 67, with knee arthritis, and a study site near you is screening. Before you sign anything, ask the study team:

1. Which of my bills go to Medicare, and which does the study pay?
2. Could I get a placebo (a shot with no medicine)?
3. How many visits, and how far?
4. Who pays if I need extra care?
5. Do I have to stop a current weight-loss medicine first, and for how long?

That last one matters. For example, Lilly’s TRIUMPH-5 listing excludes weight-loss-drug use in the 90 days before screening; that study has completed enrollment. A different study has its own rules. Never stop a prescribed medicine on your own to chase a spot. For study-level status, see our retatrutide clinical trials tracker, checked October 14, 2026, and confirm openings with the study team.

Lilly's expanded access

Expanded access lets a doctor request an unapproved drug for one patient with serious needs who can't join a trial. Lilly reviews requests case by case (Lilly Medical).

The bar is high: age 18 or older; BMI 35 or higher despite taking and tolerating the highest available dose of a weight-management medicine; at least two serious or life-threatening obesity-related conditions under treatment; and no workable retatrutide or similar-drug trial. All standard treatment options, including weight-loss surgery, must have been discussed with you. Having surgery is not a listed requirement.

A medical reason not to take retatrutide rules someone out. Access also depends on location, supply, and the individual review. Your treating doctor has to make the request. You can't apply yourself. (Lilly’s complete criteria)

Lilly says it provides the drug at no cost. That doesn't mean visits, labs, or travel are free, and it isn't Medicare coverage. Lilly also says the program ends after a potential approval and commercial launch. The full rules are in our retatrutide early access guide.

Can "research" or compounded retatrutide get around this?

No. The FDA says retatrutide can't be used in compounding under federal law and isn't part of any FDA-approved drug. A "research purposes" label does not create a covered prescription. FDA has warned sellers using that label while selling unapproved drugs to consumers for human use (FDA).

There's no safe version of a shortcut here. You don't know what's in the vial, how strong it is, or how it was stored.

If you've already used one, tell your clinician exactly what you took and when. If you have severe stomach pain, yellowing skin or eyes, or symptoms getting worse fast, get urgent medical care. (NIDDK warning signs) For a possible harmful exposure, call Poison Control at 1-800-222-1222—do not wait for symptoms. For trouble breathing, a seizure, collapse, or someone who cannot be woken, call 911. (Poison Control) More here: compounded retatrutide and how to avoid fake GLP-1 medications.

Open Enrollment is happening now. Should retatrutide change your 2027 plan?

No. Retatrutide isn't approved today, so don't choose a 2027 drug plan on a promise that it will cover it. Pick your 2027 plan for the medicines you take now. A future approval and later plan coverage would need a new check. (Current FDA status)

Medicare Open Enrollment runs October 15 to December 7, 2026, for coverage starting January 1, 2027. (Medicare enrollment dates)

Two things are worth checking while you shop:

• Your plan type. The Bridge doesn't need your plan to opt in, but your plan type must be eligible (see "Who qualifies" above).
• Your current drugs. If you take a GLP-1 for diabetes or sleep apnea, confirm the new plan's 2027 coverage and requirements in Medicare Plan Compare and with the plan. Our Part D GLP-1 coverage by plan table is 2026 background, not a verified 2027 formulary.

Paying cash while you wait

If neither the Bridge nor a covered Part D use fits, paying cash is an option for an approved GLP-1. Purchases through the discount programs discussed here don't count toward your Part D deductible or yearly limit. Commercial-insurance copay cards exclude Medicare; separate self-pay offers have their own rules. (Medicare.gov; Lilly terms; Ro self-pay terms)

Here's the honest order of options:

• You already have a doctor who will prescribe: check the manufacturer's self-pay options for Foundayo, Zepbound, or Wegovy first. You may not need another paid care membership just to get the prescription filled.
• You need a prescriber: a telehealth program can handle the prescription and follow-up, for a membership fee.

Ro is one example. Ro says people with Medicare or Medicare Advantage can join and pay cash for select GLP-1s, but Ro can't use your Medicare coverage. Its FAQ says people with Medicaid or VA coverage are not eligible—so the Medicare cash-pay statement is not an invitation for someone who also has Medicaid. Clinical suitability and service availability still need confirmation. (Ro eligibility FAQ; Ro terms) Its prices, checked October 16, 2026 (Ro pricing):

So the first-month membership plus one 30-day supply of Foundayo's lowest dose is $39 + $149 = $188 before any extra charges. You pay $39 to start; medicine is charged separately if prescribed. Extras can raise that total. After that, it's your membership plus the price for your prescribed dose. Ro says its medicine prices match LillyDirect, NovoCare, and TrumpRx. (Ro pricing; Foundayo supply terms)

The medicine and membership do not share one billing clock. In particular, a 28-day Zepbound supply is not a calendar month. These low-dose prices are not a promise of your ongoing treatment cost. (Lilly supply terms; NovoCare package terms)

Membership includes provider consultations, coaching messages, and ordered lab testing within the program. Ro's terms allow $15 per medical consultation after 24 in a year and separate charges for additional lab tests. Needles, applicable taxes or pharmacy fees can also be extra; no universal total was verified. (Ro terms, section 4; Lilly terms)

Read the prepayment terms before choosing $888 upfront. Membership renews automatically. Paid membership fees are nonrefundable, apart from the stated initial eligibility refund. Cancel at least 48 hours before renewal to avoid another membership charge. Do not treat unused prepaid months as refundable. Care continues to the end of the paid period; arrange ongoing prescription care before it ends. (Ro cancellation terms)

Need a prescriber, meet Ro's eligibility rules, and plan to pay cash? Review Ro’s current prices by dose first, then explore its care program. This does not use your Medicare drug benefit.

Want other approved options compared side by side? See the best retatrutide alternatives.

What we actually verified

Last verified October 2026 — source checks completed October 16, 2026:

• FDA status and compounding: FDA's statement on unapproved GLP-1s (content current as of October 1, 2026).
• Lilly's plans: its July 23, 2026 announcement (named uses and Q1 2027 submission plan), plus the September 29, 2026 update confirming that submission plan.
• Bridge rules: CMS pages for providers (modified August 6, 2026), pharmacies (modified August 17, 2026), and the overview (modified July 13, 2026), plus Medicare.gov's weight-loss drugs page.
• BALANCE status: CMS BALANCE page (modified September 29, 2026).
• Part D drug rules: 42 CFR 423.100 on eCFR.
• Trial costs: NCD 310.1, Medicare.gov's clinical research page, and the Medicare Advantage billing rules in 42 CFR 422.109(e).
• Expanded access: the full Lilly Medical answer, last reviewed August 26, 2026.
• Ro prices and Medicare eligibility: its public pricing page, full eligibility FAQ, and membership terms. These are provider-stated terms; we did not complete an intake or payment.
• Supply sizes and savings exclusions: Lilly's Foundayo and Zepbound terms and NovoCare's Wegovy page.
• FDA review times: the original-application goals in the PDUFA VII document.
• Zepbound’s approved use: its prescribing information, revised August 2026, for the sleep-apnea population described here.
• Other practical details: Medicare's outpatient-drug, Medigap, and enrollment guidance; Lilly's TRIUMPH-5 listing; and the linked Poison Control and NIDDK guidance.

Classification dispute: we read the September 30, 2025 court order. That is a dated ruling, not a check of every later appeal or FDA action.

What we couldn't confirm: an approval date, the type of FDA review, whether CMS will ever add retatrutide, its price, or who pays for visits and labs under expanded access. We didn't file a Medicare claim, confirm a trial site's openings, or test an individual approval. We also did not verify anyone's 2027 formulary or personal Ro checkout total.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation. Here's how we evaluate treatment paths.

Frequently asked questions

Does Medicare Part D or Medicare Advantage cover retatrutide?

No—not as a routine prescription today. Retatrutide lacks the FDA approval needed for that coverage, whether Part D is standalone or part of Medicare Advantage. Switching plans won't change that. (FDA; Part D rules)

Which BMI counts if I've already lost weight on a GLP-1?

Your BMI when you started GLP-1 treatment. CMS says that counts even if you started before Medicare or before the Bridge opened. Ask your prescriber for that record; the other Bridge rules still apply. (CMS)

Do I need a Part D denial before trying the Bridge?

No. CMS says your prescriber can have the pharmacy send the claim straight to the Bridge. Your prescriber and pharmacist should first confirm the prescription belongs there and not in regular Part D. (CMS)

Does Extra Help lower the $50 Bridge copay?

No. The Bridge runs outside Part D, so Extra Help doesn't apply. The $50 also doesn't count toward your Part D yearly limit. (CMS)

Can I use the Bridge without Medicare drug coverage?

No. You need an eligible Medicare drug plan. Call 1-800-MEDICARE or ask your pharmacist to confirm what coverage you have—a Medicare card alone isn't enough. (CMS)

Is there a pill Medicare could help pay for instead?

Foundayo tablets and Wegovy tablets are both on the Bridge for people who qualify. Neither is retatrutide, and your prescriber decides which treatment fits you. (CMS product list)

Who pays if I join a retatrutide clinical trial?

Ask the study team who supplies and pays for the drug; we did not verify a specific study's bill. Medicare can pay routine care in qualifying trials, but that does not cover investigational retatrutide itself. Your cost share depends on Original Medicare or Medicare Advantage. Get the billing plan in writing before you sign. (CMS trial rule; Medicare Advantage rules)

If retatrutide is approved for sleep apnea, would Part D cover it?

It could, but approval would not guarantee payment. Medicare's exclusion applies to weight-loss use; Zepbound's approved use for moderate-to-severe obstructive sleep apnea in adults with obesity is a separate Part D path. A future retatrutide prescription would need its own plan coverage check. (CMS Part D routing; Zepbound prescribing information)

I'm on the Bridge now. Could I switch to retatrutide later and keep paying $50?

Not under today's rules: retatrutide isn't on the list. Switching between listed GLP-1s needs a new prior authorization, not an automatic transfer of your old approval. You must remain eligible, too. Talk with your prescriber before changing anything. (CMS)

Can I appeal to get retatrutide covered now?

An appeal cannot make retatrutide an approved, covered prescription today. If an approved drug gets denied, ask which program said no: Part D has formal appeals, while the Bridge has no formal appeal and lets your prescriber resubmit corrected or new information. (Medicare drug-plan appeals; CMS Bridge process)

Sources

All checked October 16, 2026.

1. FDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current October 1, 2026)
2. Eli Lilly — Retatrutide successful in two additional Phase 3 obesity trials (July 23, 2026), and the later retatrutide update (September 29, 2026)
3. CMS — Medicare GLP-1 Bridge: Information for Providers (modified August 6, 2026)
4. CMS — Medicare GLP-1 Bridge (modified July 13, 2026)
5. Medicare.gov — Weight loss drugs
6. CMS — BALANCE Model (modified September 29, 2026)
7. eCFR — 42 CFR 423.100, Part D definitions
8. CMS — NCD 310.1: Routine Costs in Clinical Trials (current version effective May 27, 2024; underlying policy last reviewed July 2007)
9. Medicare.gov — Clinical research studies
10. Lilly Medical — Is there an expanded access program for retatrutide? (last reviewed August 26, 2026; full text inspected)
11. FDA — PDUFA VII performance goals
12. U.S. District Court, Southern District of Indiana — September 30, 2025 order in Lilly v. HHS, case 1:24-cv-01503, document 47
13. Ro — Weight loss program pricing, Medicare eligibility FAQ, and Terms of Use (terms last revised April 2, 2026; sections 3–4)
14. CMS — Bridge Information for Pharmacies (modified August 17, 2026)
15. eCFR — 42 CFR 422.109(e), Medicare Advantage clinical-trial payments
16. Medicare.gov — Outpatient prescription-drug coverage and Medigap coverage
17. Medicare.gov — Joining a plan and Open Enrollment dates and Medicare Plan Compare
18. Eli Lilly — Foundayo Coverage & Savings and Zepbound savings and self-pay terms
19. NovoCare — Wegovy patient pricing, supply sizes, and offer exclusions
20. Lilly Trials — TRIUMPH-5 listing and screening criteria (enrollment completed when checked)
21. NHLBI — BMI calculator
22. National Capital Poison Center — Immediate assistance and emergency warning signs
23. NIDDK — Symptoms that need prompt medical care
24. The RX Index — Find My GLP-1 Path and How the tool works (description and coverage limitations; no individual Medicare outcome tested)
25. Eli Lilly — Zepbound prescribing information (revised August 2026; relevant indications and starting-dose sections inspected)
26. Medicare.gov — Appeals in a Medicare drug plan